Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2014

View Archived Issues

The Vanderbilt University prepares new mAChR modulators

Novel O-GlcNAcase inhibitors disclosed by Alectos and Merck & Co.

Washington University School of Medicine to assess EDI-200 in rare genetic disorder

Pharnext's PXT-3003 obtains FDA orphan drug status

Phase III results demonstrate noninferiority of tofacitinib to etanercept in psoriasis patients

NDA for Zacras fixed-dose combination tablet for hypertension approved in Japan

FDA grants orphan drug status to Chatham Therapeutics' hemophilia B treatment

New influenza treatment Avigan approved in Japan

Researchers in India design novel agents for MDR bacterial infections

Novartis divulges new S. aureus vaccines

Laminin-gamma2 as a novel biomarker for bladder cancer

First evaluation in humans of a new necrosis inhibitor, LC28-0126

Ajinomoto Pharmaceuticals obtains approval for valsartan/cilnidipine combination in Japan

Takeda Pharmaceutical receives positive CHMP opinion for Entyvio

Tapenta receives Japanese approval for cancer pain

Takelda combination tablets approved in Japan

Novel erythropoiesis-stimulating agent GC-1113 shows efficacy in humans

CHMP recommends approval of empagliflozin for type 2 diabetes

Siltuximab receives positive CHMP opinion supporting approval in multicentric Castleman's disease

Tivicay obtains approval in Japan for HIV

FDA grants fast track designation to NeuroVax for secondary progressive MS

KB-39 as novel peptidomimetic of Bcl-2 proteins for prostate cancer

Forxiga receives regulatory approval in Japan for type 2 diabetes

Japanese approval of Lusefi for type 2 diabetes

Mochida announces Japanese approval of Treprost for PAH

CytRx initiates phase III trial of aldoxorubicin for soft tissue sarcoma

Arrowhead conducting phase IIa study of ARC-520 to treat chronic HBV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.